Iron sucrose Drug Asset Due Diligence Report 2026

This Iron sucrose Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

167

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Iron sucrose can convert its Polymer profile and Phosphates biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Iron sucrose (query alias: sucroferric oxyhydroxide)
Modality / target	Polymer; Phosphates; Phosphates modulators, Iron preparation
Highest global status	Approved
Originator	Corden Pharma Fribourg SA
Active developers	Vifor Fresenius Medical Care Renal Pharma France, Vifor SA, American Regent, Inc.

The MCP disease footprint includes Kidney Failure, Chronic, Hyperphosphatemia, Iron deficiency. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
TCTR20251229004	Phase 3	Pending (Not yet recruiting)	104	Not disclosed
NCT07657091	Phase 2	Not yet recruiting	100	increase in hb from baseline
CTR20253429	Not Applicable	已完成	48	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

EVALUATING THROMBOTIC RISK AND HEMATOCRIT EFFECT OF INTRAVENOUS IRON REPLETION IN CYTOREDUCED PATIENTS WITH POLYCYTHEMIA VERA

Not Applicable; n=710; evaluation: Positive. Reported fields: HCT level(at the time of thrombosis) = 27.3 %

A Post-Marketing Open-Label, 5 Period Crossover, Drug-Drug Interaction Study of Orally Adminstered TPOXX When Co-administered With 4 Different Phosphate Binders in Healthy Subjects

Phase 4; n=44; evaluation: not stated. Reported fields: AUC(Geometric Mean) = 16300 ng*h/mL (Geometric Coefficient of Variation, 39.6); -; -

Sociodemographic Characteristics of Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide and Other Phosphate Binders

Not Applicable; n=151870; evaluation: Positive. Reported fields: -; Age = 60.0 year

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Iron sucrose addresses Kidney Failure, Chronic, Hyperphosphatemia, Iron deficiency. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Polymer—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-02-02	康哲药业获得一线降磷创新药“维福瑞®”独家许可权利	Approved	Financial terms not disclosed
2023-06-28	維健投資與VFMCR就维福瑞®簽署許可協議。	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Iron sucrose injection and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “NMR methods for characterizing iron sucrose”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO